Jytaglen Plus (Metformin Hydrochloride, Sitagliptin)

Jytaglen Plus is an oral antidiabetic combination that targets hyperglycaemia in type 2 diabetes mellitus.

• Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose levels when used alone.
• Type 2 diabetes mellitus (add‑on to metformin): provides additional glucose reduction for patients inadequately controlled on metformin alone.
• Type 2 diabetes mellitus (add‑on to sulfonylurea or insulin): enhances overall glycaemic control when combined with other glucose‑lowering agents.

• Metformin reduces hepatic gluconeogenesis and increases peripheral insulin sensitivity, while sitagliptin blocks the dipeptidyl peptidase‑4 enzyme, raising endogenous incretin (GLP‑1 and GIP) levels. The combined actions enhance glucose‑dependent insulin secretion, suppress glucagon release, and improve overall glycaemic regulation without causing hypoglycaemia when used appropriately.

Jytaglen Plus may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Diarrhoea: loose stools, usually early in therapy.
• Headache: occasional tension‑type headache.
• Upper respiratory tract infection: nasopharyngitis symptoms.
• Dizziness: transient light‑headedness.
• Abdominal discomfort: mild cramping or bloating.

Serious or Rare Side Effects

• Lactic acidosis: rare but life‑threatening metabolic disturbance.
• Severe hypoglycaemia: especially when combined with insulin or sulfonylureas.
• Pancreatitis: acute inflammation of the pancreas.
• Allergic reactions: rash, angio‑edema, or anaphylaxis.
• Hepatic dysfunction: elevated liver enzymes or hepatitis.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, clinicians should assess patient‑specific risk factors and monitor relevant clinical parameters.

• Renal function: evaluate eGFR to avoid accumulation and lactic acidosis risk.
• Hepatic function: assess liver enzymes, as impairment may increase adverse events.
• Cardiovascular status: monitor for heart failure exacerbation.
• Concomitant hypoglycaemic agents: adjust doses to prevent severe hypoglycaemia.
• Pregnancy and lactation: weigh benefits against potential risks; use only if clearly needed.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Jytaglen Plus can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Severe renal impairment: markedly increases metformin exposure and lactic acidosis risk.
• Iodinated contrast agents: may precipitate acute kidney injury, necessitating temporary discontinuation.
• Alcohol abuse: potentiates metformin‑related lactic acidosis.

Moderate Interactions (Monitor Closely)

• Sulfonylureas or insulin: heightened hypoglycaemia; dose adjustments may be required.
• Diuretics (especially thiazides): may reduce renal clearance of metformin.
• ACE inhibitors or ARBs: monitor renal function and electrolytes.
• CYP3A4 inhibitors (e.g., ketoconazole): may increase sitagliptin levels.